The iconic success of Viagra, produced by copyright, undeniably reshaped the approach of erectile dysfunctionality, and ignited a massive growth in the pharmaceutical sector. However, now, investing in companies reliant on aging blockbuster drugs like Viagra presents a complex landscape. Off-brand competition is aggressive, substantially eroding in